Blog Posts by Daniel Gross

  • History buffs re-enact Napoleon's finest hour

    More than a thousand history buffs gathered in the Czech Republic on Saturday for a re-enactment of the Battle of Austerlitz, in which Napoleon crushed the Austrian and Russian armies in 1805.

    "We have soldiers from about twelve countries of the world, including Austria, France, Russia, but also Belgium, Italy or Poland," organiser Miroslav Jandora told AFP.

    On December 2, 1805, Napoleon's army took its rivals by surprise after feigning reluctance to fight the two armies near Austerlitz, modern day Slavkov, a town some 200 kilometres (125 miles) southeast of Prague.

    The 71,000 soldiers of Napoleon's "Grande Armee" beat the 91,000 men of the combined Russian and Austrian armies in less than six hours.

    Considered Napoleon's finest tactical masterpiece, the "Battle of the Three Emperors" left 28,000 dead.

    "Every year we re-enact a part of the battle. This year we are doing the fight for the Prace Heights, the crucial part of the battle," said Jandora.

    American actor Mark Schneider,

    Read More »from History buffs re-enact Napoleon's finest hour
  • Rain and sorrow accentuate memorial for dead at Brazil club

    On a rainy day that only accentuated the grief, 20,000 people filled a tiny stadium under umbrellas and plastic ponchos to say goodbye to members of the Chapecoense soccer club who died in a plane crash

    CHAPECO, Brazil (AP) -- On a rainy Saturday that only accentuated the grief, 20,000 people filled a tiny stadium under umbrellas and plastic ponchos to say goodbye to members of the Chapecoense soccer club who died in a plane crash.

    The accident Monday in the Colombian Andes claimed most of the team's players and staff as it headed to the finals of one of Latin America's most important club tournaments. Seventy-one of the 77 people on board died, including 19 players on the team.

    Rain-soaked mourners jammed the modest stadium with four or five times that many outside — about half the population of the southern Brazilian city of 210,000 — to pay homage to a modest club that nearly reached the pinnacle of Latin American soccer.

    Thousands also lined the roads as the coffins were driven in a procession from the airport to the stadium memorial.

    "I've been here since early morning," said 19-year-old

    Read More »from Rain and sorrow accentuate memorial for dead at Brazil club
  • This bull has an unusual method to bet on the market rising even higher

    One trader sees signs that stocks are set to keep rallying—and he has an interesting maneuver for how to profit off of his prediction.

    The S&P 500 (^GSPC) has enjoyed "a very nice uptrend," but over the past week, "we've begun to pull back," Todd Gordon of TradingAnalysis.com said Friday on CNBC's " Trading Nation ."

    However, the pullback from 2,213 down to about 2,190 has brought the market "back into support that was formed from the August and September high," he said, speaking about an area on technical charts that guard against further declines.


    Essentially, the S&P 500 Index (^GSPC) has fallen to a region that previously served as a level of resistance—and it is a tenet of technical analysis that old levels of resistance become new levels of support.

    This implies that the market will likely move higher from here, and it has Gordon looking to make a bullish play on the SPY ETF (NYSE Arca: SPY), which tracks the S&P 500.

    Often, options traders who are bullish

    Read More »from This bull has an unusual method to bet on the market rising even higher
  • The Mazda CX-9 is a terrific, stylish family SUV — with just a single problem

    Mazda CX-9(An excellent three-row crossover — with style!Matthew DeBord/BI)
    Here's the verdict on the Mazda CX-9 crossover, the automaker's largest car with room for seven passengers in its three rows: It's terrific!

    Now the bad, and there's only one small complaint: the Skyactiv-G 2.5-liter, four-cylinder turbocharged engine cranks out only 250 horsepower, less than what you'd get in a competing vehicle with a V6 (think GMC Acadia, Ford Explorer, Honda Pilot). You just don't have that oomph you might expect from a people-and-stuff-hauler.

    For what it's worth, CX-9 owners will be perfectly happy with the 23mpg-combined fuel economy they get from their crossover and not entirely miss the additional power. But then again, we've had this genre of three-row SUV for a while now and with the bigger ride comes the expectation of power.

    Mazda CX-9(Looks as good as a BMW.Matthew DeBord/BI)

    With the CX-3, CX-5, and CX-9 making up its crossover lineup, Mazda has its bases well covered in the red-hot segment. The

    Read More »from The Mazda CX-9 is a terrific, stylish family SUV — with just a single problem
  • SAN DIEGO--(BUSINESS WIRE)--

    Seattle Genetics, Inc. (SGEN), a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) combination therapy in frontline diffuse large B-cell lymphoma (DLBCL) at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, expressed on several types of non-Hodgkin lymphoma. ADCETRIS is currently not approved for the treatment of DLBCL.

    Data from the phase 2 study in newly diagnosed intermediate-high or high-risk DLBCL included the evaluation of ADCETRIS in combination with either rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine and prednisone (referred to as RCHOP) in 51 patients (Part 1); or RCHP (removing the vincristine) in

    Read More »from Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting
    Contact:
    Seattle Genetics, Inc.
    Investors:
    Peggy Pinkston, 425-527-4160
    ppinkston@seagen.com
    or
    Media:
    Tricia Larson, 425-527-4180
    tlarson@seagen.com

  • Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases

    Findings Presented at the 70th Annual Meeting of the American Epilepsy Society

    HOUSTON, Dec. 3, 2016 /PRNewswire/ -- Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today announced that findings from its first case study of an individualized approach to the identification of candidate therapies for a patient with epileptic encephalopathy caused by a mutation in the SCN8A gene were presented at the 70th Annual Meeting of the American Epilepsy Society in Houston, TX, December 2-6, 2016. 

    Pairnomix, LLC (PRNewsFoto/Pairnomix, LLC)

    Pairnomix' unique process involves creating a model of a patient's genetic mutation, learning about the functional consequences of that mutation, and testing approved drugs against the model to identify potential new treatment options.  Findings are provided to the patient's physician so together they can make better-informed healthcare decisions.

    "We are very pleased to share these findings with the epilepsy community, and are gratified to be able to illustrate that it is possible to

    Read More »from Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases
  • Scientists have made a bizarre lifeform that bonds carbon to silicon

    silicon carbide alien life illustration science

    Lei Chen and Yan Liang/BeautyOfScience.com; Caltech

    An illustration of a fictional organosilicon-based blob beast.

    Scientists have coaxed life to do something it has never done before: bond silicon to carbon.

    You’re probably already familiar with a few products products that use carbon-silicon, or organosilicon: glues, caulks, and pesticides, to name a few.

    But the new biological trick, which was forcefully evolved in bacteria, is safer and 15 times more efficient than synthetic, industrial chemistry at making organosilicons that are useful to industry and research.

    This new bioengineering by Caltech researchers, described in the journal Science, may not improve the prospects of silicon-based alien life — contrary to a colorful illustration sent to members of the press (shown here) — but it could enable biologists to ask sci-fi-level questions.

    “Why does life look the way it does? We can start asking, for the first time, what happens if you put silicon in place of carbon in

    Read More »from Scientists have made a bizarre lifeform that bonds carbon to silicon
  • U.S. Consumers Are Spending Like Crazy so Far This Holiday Season

    Editors' pick: Originally published Nov. 24.

    Updated from Nov. 25 with new Adobe sales data.

    U.S. consumers have stepped up big-time to shop so far this holiday season.  

    Online sales for Thanksgiving Day and Black Friday reached $5.27 billion, up a strong 17.7% from last year, according to new data Saturday from Adobe. Black Friday set a new record by ringing up $3.34 billion in sales, an increase of 21.3% year over year. 

    A good portion of the online shopping is being done on mobile devices. Black Friday became the first day in retail history to notch over $1 billion in mobile sales at $1.2 billion, up 33% from a year ago.

    The results are based on aggregated and anonymous data from 22.6 billion visits to retail websites.

    "Shoppers hit the buy button at unprecedented levels as conversion rates were up nearly a full percent across all devices in the evening hours on Black Friday," said Tamara Gaffney, Principal Analyst and Director at Adobe Digital Insights in a statement.

    Read More »from U.S. Consumers Are Spending Like Crazy so Far This Holiday Season
  • Will Solar Stocks See A DotCom Style Bubble?

    Solar power is starting to look a little like the internet – way overhyped at first, generally unprofitable initially, but eventually a really big deal. Only time will tell what happens in the space of course, but there are indications that solar is becoming a seriously viable industry in the long-term.

    One of the best indications that solar is becoming a real business is the adoption of large scale solar by various big companies. For instance, the SEIA recently noted that solar use by major firms the group tracks expanded from 300 MW in 2012 to over 1 GW in 2016. That total represents 16 percent of all non-residential, non-utility-scale solar PV capacity in the U.S.

    Solar power is being particularly adopted by mass big box retailers – Walmart and Target for instance are the largest two users of solar according to the SEIA with 147.5 MW and 145 MW respectively. That makes sense as the large flat roofs of big box stores present an obvious opportunity for solar, and the firm’s low cost

    Read More »from Will Solar Stocks See A DotCom Style Bubble?
  • New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

    Data on First Smoothened Inhibitor to Show Clinical Benefit in This Patient Population to be Presented During Oral Session at 2016 ASH Annual Meeting

    NEW YORK--(BUSINESS WIRE)--

    Today, Pfizer Inc. (PFE) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly increased overall survival (OS) when compared to LDAC alone in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who were ineligible for intensive chemotherapy (HR: 0.501, 80% CI: 0.384, 0.654, one-sided log rank p-value 0.0003). Glasdegib is the first SMO inhibitor to show clinical benefit in this patient population. These data were presented today at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.

    Glasdegib is an investigational oral therapy that inhibits the SMO receptor, thereby disrupting the hedgehog (Hh) pathway. The results presented are from a

    Read More »from New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Contact:
    Pfizer Inc.
    Media:
    Sally Beatty, 212-733-6566
    or
    Investors:
    Ryan Crowe, 212-733-8160

Pagination

(1,824,365 Stories)
 
Recent Quotes
Symbol Price Change % Chg 
Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
You need to enable your browser cookies to view your most recent quotes.
 
Sign-in to view quotes in your portfolios.

Featured Blog Posts